Literature DB >> 8685942

Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization.

J Brauker1, L A Martinson, S K Young, R C Johnson.   

Abstract

Immunoisolation of xenogeneic pancreatic islets within membrane-bound devices has been proposed as an approach to cure diabetes. We examined the local response to implanted xenografts and allografts in comparison with isografts in diffusion chambers with 0.4-microm pore membranes when implanted into epididymal fat pads of rats. These membranes prevented host cell entry into the device but did not prevent passage of large molecules such as IgG and IgM. Well-differentiated allogeneic tissues (Sprague-Dawley rat embryonic lung implanted into Lewis rats) survived for 1 year when implanted in intact devices, but similar tissues were destroyed within 3 weeks when implanted within devices with holes poked in the membrane to allow host cell contact. In contrast, xenografts (CF1 mouse embryonic lung implanted into Lewis rats) were destroyed within 3 weeks even when implanted in devices with intact membranes. The death of the xenogeneic tissues was accompanied by a severe local accumulation of inflammatory cells and a decrease in local vascularization. When isogeneic tissues (Lewis rat embryonic lung implanted in Lewis rats) were mixed with xenogeneic tissues, a local inflammatory response occurred and both iso- and xenogeneic tissues were destroyed within 5 weeks. These results suggest the possibility that xenografts are killed by local accumulation of inflammatory cells, perhaps mediated by the release of antigens from the tissues within the device and presentation by an indirect pathway. The observation that the local response to xenografts is sufficient to kill isografts complicates issues of immunoprotection, suggesting that successful immunoisolation will require membranes that not only provide protection of the encapsulated tissues from the host immune system but also have properties that diminish the release of xenogeneic antigens.

Entities:  

Mesh:

Year:  1996        PMID: 8685942     DOI: 10.1097/00007890-199606270-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

Review 1.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 2.  Islet transplantation and encapsulation: an update on recent developments.

Authors:  Vijayaganapathy Vaithilingam; Bernard E Tuch
Journal:  Rev Diabet Stud       Date:  2011-05-10

Review 3.  Islet and stem cell encapsulation for clinical transplantation.

Authors:  Rahul Krishnan; Michael Alexander; Lourdes Robles; Clarence E Foster; Jonathan R T Lakey
Journal:  Rev Diabet Stud       Date:  2014-05-10

Review 4.  Advances in islet encapsulation technologies.

Authors:  Tejal Desai; Lonnie D Shea
Journal:  Nat Rev Drug Discov       Date:  2016-12-23       Impact factor: 84.694

Review 5.  The journey of islet cell transplantation and future development.

Authors:  Anissa Gamble; Andrew R Pepper; Antonio Bruni; A M James Shapiro
Journal:  Islets       Date:  2018-02-05       Impact factor: 2.694

6.  Inconsistent formation and nonfunction of insulin-positive cells from pancreatic endoderm derived from human embryonic stem cells in athymic nude rats.

Authors:  Aleksey V Matveyenko; Senta Georgia; Anil Bhushan; Peter C Butler
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-06-29       Impact factor: 4.310

7.  Anti-tumor therapy with macroencapsulated endostatin producer cells.

Authors:  Danielle B Rodrigues; Roger Chammas; Natália V Malavasi; Patrícia L N da Costa; Rosa M Chura-Chambi; Keli N Balduino; Ligia Morganti
Journal:  BMC Biotechnol       Date:  2010-03-02       Impact factor: 2.563

8.  Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies.

Authors:  Seung-Hee Lee; Ergeng Hao; Alexei Y Savinov; Ifat Geron; Alex Y Strongin; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

9.  Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.

Authors:  C Gysemans; K Stoffels; A Giulietti; L Overbergh; M Waer; M Lannoo; U Feige; C Mathieu
Journal:  Diabetologia       Date:  2003-07-17       Impact factor: 10.122

10.  Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta).

Authors:  Alice F Tarantal; C Chang I Lee; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-07-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.